Cognition Therapeutics

CGTX · Nasdaq · United States

Share price · CGTX

$0.60-0.38 (-38.89%) 3M

close as of 2026-11-18 · 24h delayed · vol 340K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CGTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 15 Oct 2026-5.7%
  2. 24 Jun 2026-38.2%
  3. 1 Apr 2026+17.4%

    Nothing announced by CGTX that day or the session before.

  4. 31 Mar 2026+27.7%

    Nothing announced by CGTX that day or the session before.

  5. 30 Mar 2026-18.6%

    Nothing announced by CGTX that day or the session before.

  6. 27 Mar 2026-32.4%
  7. 30 Jan 2026-12.1%

    Nothing announced by CGTX that day or the session before.

  8. 23 Dec 2025-11.9%

    Nothing announced by CGTX that day or the session before.

Share of unusual movement by asset

For each asset, the share of CGTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Zervimesine
events and moves
2316%
Other company news (earnings, financing, releases naming no asset)—15%
Sessions with no dated event—69%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Sigma-2 receptor complexSmall molecule
Alzheimer's DiseaseDementia with Lewy Bodies

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
May 2027 (1)
ZervimesinePhase 2Early Alzheimer's Disease
Est. primary completion 2027-05-31 · NCT05531656 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 May 2025Topline resultZervimesinePhase 2 MAGNIFY (NCT05893537) of zervimesine in geographic atrophy: topline results
Cognition Therapeutics · Source ↗
29 July 2024Topline resultZervimesineSHINE (NCT03507790) Phase 2: first prespecified efficacy test not statistically significant
Cognition Therapeutics · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$5.1M$31M$4.1M-$3.3M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$5.1M$35M$3.9M-$3.0M operating cash flowreport ↗
2026-Q1—$6.1M$31M$4.6M-$5.5M operating cash flowreport ↗
2025-Q3—$3.8M$40M$4.9M-$5.7M operating cash flowreport ↗
2025-Q2—$11M$12M$6.7M-$5.6M operating cash flowreport ↗
2025-Q1—$11M$16M$8.5M-$9.9M operating cash flowreport ↗
2024-Q3—$11M$22M$9.9M-$6.8M operating cash flowreport ↗
2024-Q2—$12M$29M$7.0M-$6.0M operating cash flowreport ↗
2024-Q1—$11M$35M$9.2M-$7.2M operating cash flowreport ↗
2023-Q3—$12M$33M$6.8M-$4.2M operating cash flowreport ↗
2023-Q2—$8.5M$37M$4.7M-$3.7M operating cash flowreport ↗
2023-Q1—$5.4M$39M$6.2M-$2.7M operating cash flowreport ↗
2022-Q3—$8.3M$47M$6.6M$0 operating cash flowreport ↗
2022-Q2—$9.1M$46M$5.8M-$5.4M operating cash flowreport ↗
2022-Q1—$6.5M$52M$3.8M-$3.0M operating cash flowreport ↗
2021-Q3—$3.7M$8.3M$3.1M-$2.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$37M$37M$5.9M-$25M operating cash flowreport ↗

Cognition Therapeutics reported no revenue for fiscal year 2025, with R&D spend of $37.19M, down 10.8% YoY. Cash and equivalents stood at $37M, and the company reported a net loss of $23.49M. No analyst consensus figures were provided.

The company is advancing zervimesine for DLB psychosis, with an FDA Division of Psychiatry meeting expected by mid-2026, and has completed enrollment in the Phase 2 START trial in early Alzheimer's disease, with topline results expected in 2027. Management estimates sufficient cash to fund operations through the second quarter of 2027.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$42M$25M$8.5M-$28M operating cash flowreport ↗
2023-FY—$37M$30M$6.5M-$16M operating cash flowreport ↗
2022-FY—$30M$42M$5.3M-$19M operating cash flowreport ↗
2021-FY—$19M$55M$2.9M-$3.6M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($32K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-17Fletcher Aaron G.L.; BIOS Capital Management, LP; BIOS Advisors GP, LLC; Bios Equity Partners, LP; BIOS Fund I, LP; BIOS Fund II QP, LP; BIOS Memory SPV I, LP; Bios Equity Partners II, LP; BIOS Fund II, LP; BIOS Fund I QP, LP · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% ownerAward / grant25,000——Form 4
2026-06-17RICHSTONE ELLEN B · directorAward / grant25,000——Form 4
2026-06-17Wallace Peggy · directorAward / grant25,000——Form 4
2026-06-17Monia Brett P · directorAward / grant25,000——Form 4
2026-06-17Khattar Jack A. · directorAward / grant25,000——Form 4
2026-05-01Doyle John Brendan · Chief Financial OfficerTax withholding8,567$1.28$11KForm 4
2026-04-16Caggiano Anthony · Chief Medical OfficerOpen-market purchase10,000$1.11$11KForm 4
2026-04-16Ricciardi Lisa · director, CEO & PresidentOpen-market purchase9,175$1.10$10KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 75 reporting institutions held 21.4M shares ($16.1M, 22.5% of shares outstanding).

#InstitutionSharesValue
1BIOS Capital Management, LP6,000,000$4.6M
2VANGUARD CAPITAL MANAGEMENT LLC3,001,787$2.3M
3DAVENPORT & Co LLC2,892,808$2.2M
4RENAISSANCE TECHNOLOGIES LLC1,117,136$848K
5Chescapmanager LLC997,029$757K
6BlackRock, Inc.968,362$735K
7GEODE CAPITAL MANAGEMENT, LLC920,208$699K
8Hilton Capital Management, LLC548,950$417K
9VANGUARD FIDUCIARY TRUST CO463,684$352K
10Dauntless Investment Group, LLC431,000$327K
11CM Management, LLC400,000$304K
12JANE STREET GROUP, LLC370,140$281K
13Sigma Planning Corp337,765$257K
14STATE STREET CORP314,483$239K
15AMERICAN FINANCIAL GROUP INC205,000$156K